JOHANNESBURG and PITTSBURGH, Dec. 31, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced that its subsidiary in India,
Mylan Laboratories Ltd., a leading manufacturer of antiretroviral
(ARV) drugs, has been selected, through its South African-based
subsidiary Mylan (Proprietary) Limited, as one of the leading
suppliers of ARV medications to the South African National
Department of Health for the tender period April 1,
2015 to March 31, 2018.
As a part of this award, Mylan will supply the South African
Government with triple therapy fixed dose combination (FDC)
treatments. Mylan was previously selected as a leading supplier for
the 2013/2014 tender and is pleased to continue its support of the
Government's initiative to increase the number of patients on
triple therapy FDC treatment regimens in South Africa, as such
regimens can simplify treatment and improve patient adherence.
Mylan CEO Heather Bresch commented, "Mylan's selection
by the South African Department of Health as a leading supplier of
ARVs reinforces our longstanding commitment to fighting HIV/AIDS in
both South Africa and around the
world. We are proud of our progress to date in stemming the tide of
the disease with approximately 40% of those being treated in the
developing world today depending on our ARV products, but with more
than 35 million people affected globally there is more work to be
done. This tender supports our mission to provide the world's 7
billion people access to high quality medicine, including
affordable ARVs, and we look forward to working with the South
African Government on this important effort."
Guillaume van Niekerk,
Mylan South Africa managing director
and vice president, added, "We applaud the South African
Government's tremendous efforts the past two years in increasing
the number of individuals who have been tested and treated for
HIV/AIDS. Mylan South Africa looks
forward to partnering with the Government again and continuing our
role as a leading ARV supplier. This new tender represents our
ability to reliably supply the South
Africa market with high quality, affordable ARV medications,
and our dedication to making a positive change in the local
HIV/AIDS community."
Mylan supplies ARV drugs to more than 100 countries around the
world. In 2012, Mylan entered the South African market with a
comprehensive portfolio of ARV medications, consisting of first-
and second-line adult and pediatric therapies, including several
dual and triple FDCs.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 25,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at mylan.com
This press release may contain "forward-looking statements,"
including statements about the Company's future operations, planned
activities, anticipated growth, market opportunities, strategies,
competition, and other expectations. These statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Because forward-looking statements
inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to: the effect of
any changes in customer and supplier relationships and customer
purchasing patterns; changes in industry regulations and
relationships with government authorities; changes in third-party
relationships; the impacts of competition; changes in economic and
financial conditions of the Company's business; uncertainties and
matters beyond the control of management; and the other risks
detailed in the company's filings with the Securities and Exchange
Commission. The Company undertakes no obligation to update any
statements herein for revisions or changes after the date of this
release.
Video - http://youtu.be/RiFbPU98AHo
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/south-african-national-department-of-health-selects-mylan-as-a-leading-supplier-for-20152018-antiretroviral-tender-300014545.html
SOURCE Mylan Inc.